Cost-effectiveness of a 13-valent pneumococcal conjugate vaccine compared with currently available pneumococcal conjugate vaccines in Indian children.

ABSTRACT:

Objectives

Four pneumococcal conjugate vaccines (PCVs) are available for infant immunization in India's private sector: a 13-valent (PCV13-PFE), two 10-valent (PCV10-GSK, PCV10-SII), and a 14-valent (PCV14-BE).

Methods

Based on the India label dosing for each, a decision-analytic Markov model was used to compare the health and economic impacts and cost-effectiveness of PCV13-PFE (3+1) vs PCV10-SII (3+0), PCV10-GSK (3+1), or PCV14-BE (3+0). Pneumococcal disease (PD) incidence, serotype distribution, costs, and utility inputs were derived from published studies and local evidence. Adjustment for the estimated direct vaccine effects following the specified dosing schedules was applied to PCV10-SII and PCV14-BE. A willingness-to-pay threshold of INR 590,949 per quality-adjusted

SUBMITTER: Taur SR 

PROVIDER: S-EPMC12357320 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature